{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:24:11Z","timestamp":1791329051294,"version":"4.3.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4317-4","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T09:03:41Z","timestamp":1565946221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Elvis Dzelamonyuy","family":"Chem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Claire","family":"Van Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"4317_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/thx.2005.045963","volume":"61","author":"A Faustini","year":"2006","unstructured":"Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158\u201363.","journal-title":"Thorax."},{"key":"4317_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S2213-2600(15)00063-6","volume":"3","author":"A Zumla","year":"2015","unstructured":"Zumla A, Chakaya J, Centis R, D\u2019Ambrosio L, Mwaba P, Bates M, Kapata N, et al. Tuberculosis treatment and management\u2014an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015;3:220\u201334.","journal-title":"Lancet Respir Med"},{"key":"4317_CR3","unstructured":"World Health Organization. Global Tuberculosis Report. Geneva; 2018. \n                    https:\/\/www.who.int\/tb\/publications\/global_report\/en\/\n                    \n                  . Accessed 04 Dec 2018."},{"key":"4317_CR4","unstructured":"World Health Organization. Multidrug-resistant tuberculosis (MDR-TB) 2017 update. 2017. \n                    https:\/\/www.who.int\/tb\/challenges\/mdr\/MDR-RR_TB_factsheet_2017.pdf\n                    \n                  . Accessed 03 Feb 2018."},{"key":"4317_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12916-016-0704-5","volume":"14","author":"F Gehre","year":"2016","unstructured":"Gehre F, Out J, Kendall J, Forson A, Kwara A, et al. The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance. BMC Med. 2016;14:160.","journal-title":"BMC Med"},{"issue":"8","key":"4317_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.5588\/ijtld.15.0123","volume":"19","author":"P Isaakidis","year":"2015","unstructured":"Isaakidis P, Casas EC, Das MS, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969\u201378.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"4317_CR7","doi-asserted-by":"publisher","first-page":"e82235","DOI":"10.1371\/journal.pone.0082235","volume":"9","author":"Yonatan Moges Mesfin","year":"2014","unstructured":"Mesfin YM, Hailemariam D, Biadglign S, Kibret KT. Association between HIV\/AIDS and Multi-Drug Resistance Tuberculosis: A Systematic Review and Meta-Analysis. PLoS ONE. 2014;9(1):e82235. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0082235\n                    \n                  .","journal-title":"PLoS ONE"},{"issue":"s1","key":"4317_CR8","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/518665","volume":"196","author":"Charles\u00a0D. Wells","year":"2007","unstructured":"Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis\u2014the perfect storm. JID. 2007;196(Suppl 1):S86\u2013S107. \n                    https:\/\/doi.org\/10.1086\/518665\n                    \n                  .","journal-title":"The Journal of Infectious Diseases"},{"issue":"6","key":"4317_CR9","first-page":"640","volume":"9","author":"KF Laserson","year":"2005","unstructured":"Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4317_CR10","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant Tuberculosis. Geneva; 2008. \n                    https:\/\/www.who.int\/tb\/challenges\/mdr\/programmatic_guidelines_for_mdrtb\/en\/\n                    \n                  . Accessed 16 June 2018."},{"key":"4317_CR11","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2016. 2016 recommendations for a public health approach second edition Geneva. \n                    https:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/\n                    \n                  . Accessed 16 June 2018."},{"issue":"4","key":"4317_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7196\/SAMJ.6835","volume":"103","author":"D Evans","year":"2013","unstructured":"Evans D. Ten years on ART \u2013 where to now? S Afr Med J. 2013;103(4):229\u201331. \n                    https:\/\/doi.org\/10.7196\/SAMJ.6835\n                    \n                  .","journal-title":"S Afr Med J"},{"issue":"10","key":"4317_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046943","volume":"7","author":"H Satti","year":"2012","unstructured":"Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One. 2012;7(10):e46943. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0046943\n                    \n                  .","journal-title":"PLoS One"},{"key":"4317_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12879-015-1214-3","volume":"15","author":"T Umanah","year":"2015","unstructured":"Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe tropical disease hospital Johannesburg, South Africa. BMC Infect Dis. 2015;15:478.","journal-title":"BMC Infect Dis"},{"key":"4317_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","volume":"70","author":"D Meressa","year":"2015","unstructured":"Meressa D, Hurtado RM, Andrews JR, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia-an observational cohort study. Thorax. 2015;70:1181\u20138.","journal-title":"Thorax."},{"issue":"3","key":"4317_CR16","doi-asserted-by":"publisher","first-page":"e0144249-e","DOI":"10.1371\/journal.pone.0144249","volume":"11","author":"M Van der Walt","year":"2016","unstructured":"Van der Walt M, Lancaster J, Shean K. Tuberculosis Case Fatality and Other Causes of Death among Multidrug-Resistant Tuberculosis Patients in a High HIV Prevalence Setting, 2000\u20132008, South Africa. PLoS One. 2016;11(3):e0144249-e.","journal-title":"PLoS One"},{"issue":"1","key":"4317_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/QAI.0000000000001169","volume":"74","author":"SS Shin","year":"2017","unstructured":"Shin SS, Modongo C, Boyd R, Caiphus C, Kuate L, Kgwaadira B, Zetola NM. High treatment success rates among HIV-infected Multidrugresistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006\u20132013. J Acquir Immune Defic Syndr. 2017;74(1):65\u201371.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4317_CR18","doi-asserted-by":"publisher","unstructured":"Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FGJ, Joloba M, Gomez GB. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health. 2015;(15):1471\u20132458. \n                    https:\/\/doi.org\/10.1186\/s12889-015-1614-8\n                    \n                  .","DOI":"10.1186\/s12889-015-1614-8"},{"issue":"1","key":"4317_CR19","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1038\/s41598-018-23344-z","volume":"8","author":"JP Samuels","year":"2018","unstructured":"Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018;8(1):4980.","journal-title":"Sci Rep"},{"issue":"4","key":"4317_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.13105\/wjma.v5.i4.80","volume":"5","author":"Claudio Luchini","year":"2017","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Meta-Anal. 2017;5(4):80\u20134. \n                    https:\/\/doi.org\/10.13105\/wjma.v5.i4.80\n                    \n                  .","journal-title":"World Journal of Meta-Analysis"},{"key":"4317_CR21","unstructured":"National Heart, Lung and Blood Institute. Study Quality assessment tools. Quality assessment of controlled intervention studies. Online. Avaialable at: \n                    https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools\n                    \n                  . Accessed 08 May 2018."},{"issue":"8","key":"4317_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/cid\/cix1125","volume":"66","author":"JCM Brust","year":"2018","unstructured":"Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, et al. Improved survival and cure rates with concurrent treatment for multidrug-resistant tuberculosis-human immunodeficiency virus coinfection in South Africa. Clin Infect Dis. 2018;66(8):1246\u201353.","journal-title":"Clin Infect Dis"},{"issue":"35","key":"4317_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.5897\/AJPP2015.4298","volume":"9","author":"P Mugabo","year":"2015","unstructured":"Mugabo P, Adewumi AO, Theron D, Burger A, Van ZL. Do HIV infection and antiretroviral therapy influence multidrug-resistant tuberculosis treatment outcomes? Afr J Pharm Pharmacol. 2015;9(35):875\u201380.","journal-title":"Afr J Pharm Pharmacol"},{"issue":"5","key":"4317_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/trstmh\/trv025","volume":"109","author":"TA Umanah","year":"2015","unstructured":"Umanah TA, Ncayiyana JR, Nyasulu PS. Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe tropical disease hospital Johannesburg, South Africa. Trans R Soc Trop Med Hyg. 2015;109(5):340\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4317_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5588\/ijtld.13.0627","volume":"8","author":"N Padayatchi","year":"2014","unstructured":"Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT trial. Int J Tuberc Lung Dis. 2014;8:147\u201354.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4317_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02363-2016","volume":"49","author":"C Magis-Escurra","year":"2017","unstructured":"Magis-Escurra C, G\u00fcnther G, Lange C, et al. Treatment outcomes of MDR-TB and HIV co-infection in Europe. Eur Respir J. 2017;49:1602363.","journal-title":"Eur Respir J"},{"issue":"9","key":"4317_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/hiv.12256","volume":"16","author":"M Mansfeld","year":"2015","unstructured":"Mansfeld M, Skrahina A, Shepherd L, et al. Major differences in organization and availability of health care and medicines for HIV\/TB coinfected patients across Europe. HIV Med. 2015;16(9):544\u201352. \n                    https:\/\/doi.org\/10.1111\/hiv.12256\n                    \n                  .","journal-title":"HIV Med"},{"issue":"12","key":"4317_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145380","volume":"10","author":"AM Efsen","year":"2015","unstructured":"Efsen AM, Schultze A, Post FA, et al. Major challenges in clinical management of TB\/HIV Coinfected patients in Eastern Europe compared with Western Europe and Latin America. PLoS One. 2015;10(12):e0145380. Published 2015 Dec 30. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0145380\n                    \n                  .","journal-title":"PLoS One"},{"issue":"11","key":"4317_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112017","volume":"9","author":"A Odone","year":"2014","unstructured":"Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One. 2014;9(11):e112017. Published 2014 Nov 12. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0112017\n                    \n                  .","journal-title":"PLoS One"},{"key":"4317_CR30","first-page":"420","volume":"14","author":"T Heller","year":"2010","unstructured":"Heller T, Lessells R, Wallrauch C, B\u00e4rnighausen T, Cooke GS, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14:420\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4317_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1471-2334-14-333","volume":"14","author":"P Weiss","year":"2014","unstructured":"Weiss P, Chen W, Cook VJ, Johnston JC. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis. 2014;14:333.","journal-title":"BMC Infect Dis"},{"key":"4317_CR32","doi-asserted-by":"crossref","unstructured":"Efsen AM, Schultze A, Miller RF, Panteleev A, Skrahin A, Podlekareva DN, et al. Management of MDR-TB in HIV co-infected patients in Eastern Europe: results from the TB:HIV study. J Inf Secur. 2018;76(1):44\u201354.","DOI":"10.1016\/j.jinf.2017.10.007"},{"key":"4317_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12879-017-2230-2","volume":"17","author":"A Omowunmi","year":"2017","unstructured":"Omowunmi A, Mariya B, Viatcheslav K, Natasha R, Timothy PF, Vasyl P, Megan BM. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect Dis. 2017;17:129. \n                    https:\/\/doi.org\/10.1186\/s12879-017-2230-2\n                    \n                  .","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4317-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T19:09:23Z","timestamp":1597432163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4317"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4317-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.10131\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10131\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was a review of existing records. No ethical clearance was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"723"}}